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Summary 
Many major histocompatibility complex (MHC) polymorphisms originate from ancient structures 
that predate speciation.  As a consequence, members of the Mhc-DRB1*03 allelic lineage are not 
only present in humans but in chimpanzees and rhesus macaques as well. This emphasizes that 
Mhc-DRBl*03 members must have been present in a common ancestor of these primate species 
that lived about 30 million years ago. Due to the accumulation of genetic variation, however, 
alleles of the Mhc-DRBI*03 lineage exhibit species-unique sequences. To investigate the biological 
importance of such conservation and variation, we have studied both the binding and antigen 
presentation capacity of various  trans-species Mhc-DRB1*03 lineage members. Here we show 
that p3-13 of the 65-kD heat-shock protein (hsp65) of Mycobacterium leprae and M. tuberculosis 
binds not only to HLA-DR17(3) but also to some chimpanzee and rhesus macaque class II-positive 
cells. Comparison of the corresponding human, chimpanzee, and rhesus macaque Mhc-DRBl*03 
lineage members revealed the presence of uniquely shared amino acid residues, at positions 9-13 
and 26-31, of the antigen-binding site that are critical for p3-13 binding. In addition it is shown 
that several nonhuman primate antigen-presenting cells that bind p3-13 can activate HLA-DR17- 
restricted T cells. Certain amino acid replacements, however, in Mhc-DRBl*03 lineage members 
did not influence peptide binding or T  cell recognition. Therefore, these studies demonstrate 
that some polymorphic amino acid residues (motifs) within the antigen-binding site of MHC 
class II molecules that are crucial for peptide binding and recognition by the T  cell receptor 
have been conserved for over 30 million years. 
p eptides are able to bind to specificity pockets within the 
peptide-binding site of MHC molecules (1-3).  The pro- 
posed model for the structure of MHC class II molecules 
(4), which has been determined based on the resolution of 
the structure of HLA class I (5), shows that most polymorphic 
amino acid residues map within the peptide-binding site. Mhc 
polymorphism thus will result in the differential  selection 
of peptides available for T  cell recognition. 
Mycobacterial  heat-shock proteins (hsp) 1 are dominant T 
cell antigens in the response of healthy as well as mycobac- 
terial disease-affected individuals (6-8). The antigenicity of, 
but also the high homology  between, several mammalian and 
bacterial  hsp has led to the hypothesis that T  cells initially 
1 Abbreviations used in this paper: B-LCL, B lymphoblastoid  call line; HA, 
hemagglutinin;  hsp, heat-shock protein. 
triggered by an infection may become crossreactive with self- 
peptides. Eventually this results in, or may even prolong, au- 
toimmune responses at local sites of inflammation (9). The 
best characterized  mycobacterial hsp is hsp65 (10), which is 
recognized in the context of several different HLA-DR. mol- 
ecules by CD4-positive, antigen-specific  T  cells (7,  8). 
Previously it was reported that hsp65 p3-13 is immuno- 
dominant in the mycobacterium-specific  T  cell response of 
HLA-DR17(3) -positive individuals and is not recognized in 
the context of any other HLA-DR molecule (11). This DR17- 
restricted T cell recognition most probably arises from the 
fact that p3-13 binds to motifs uniquely present in HLA- 
DR17 molecules (12). 
Comparison of nucleotide sequences showed a high de- 
gree of similarity between some nonhuman primate Mhc al- 
leles  and certain  HLA  orthologs (13-17).  The degree of 
similarity between related Mhc class II alleles of different spe- 
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distinct lineages of the same species, as is consistent with the 
trans-species hypothesis (18). This hypothesis states that closely 
related Mhc alleles in different species originate from common 
ancestral  alleles, predating the divergence of these species. 
Trans-species alleles that group into a lineage are generally 
unique to a species due to the accumulation of genetic varia- 
tion, mainly caused by point mutations or crossing over events 
(19-21). 
In this study we have investigated the functional impor- 
tance of these conserved motifs that are present in the diverged 
members of the Mhc-DRB1 *03 aUelic lineage of humans, chim- 
panzees (Pan troglodytes), and rhesus macaques (Macaca mulatta). 
"['he capacity of different primate Mhc-DRBI*03  members 
to bind and present hsp65  p3-13 was analyzed using non- 
human  primate-derived EBV-B  lymphoblastoid cell  lines 
(BLCL) as "biomutant" APC. As the corresponding nucleo- 
tide sequences of the Mhc-DRB molecules of these cells have 
been determined (20,  21), it is  now possible  to pinpoint 
the essential Mhc-DRBI*O3-encoded residues involved in the 
binding of hsp65 p3-13.  Moreover, the functionality of the 
p3-13 binding was analyzed in T cell stimulation assays using 
HLA-DR17-restricted, hsp65  p3-13-reactive  human T  cell 
clones and nonhuman primate-derived EBV-BLCL as APC. 
Materials  and Methods 
Synthetic Peptides.  Synthesis  of p3-13 (KTIAYDEEARR) and 
p307-319 (PKYVKQNTLKLAT)  has been described (12). In short, 
peptides were made by standard solid-phase  methods on a 10e10tide 
synthesizer using Fmoc amino acid pentafluorophenylesters  (Cam- 
bridge Research Biochemicals  Ltd., Cambridge,  England). The long 
chain biotinylated analogues of the peptides were made by coup- 
ling of 6-(Fmoc amino) hexanoic acid and biotin (Serva, Heidel- 
berg, Germany), respectively,  at the end of the synthesis. The pe10- 
tides were purified by gelfiltration chromatography on a Sephadex 
G-25 (superfine) column (Pharmacia, Uppsala, Sweden) followed 
by reversed-phase HPLC (C18) purification, and analyzed by fast 
atom bombardment mass spectrometry. 
Binding Assay.  In the binding assay  (12, 22), EBV-BLCL  (3  x 
10S/sample) were incubated with the biotinylated peptide (50/~M) 
at 37~  for 4 or 20 h. As a control, cells were labeled in each ex- 
periment  with a biotinylated mAb  specific for HLA-DR (5/A; 
Becton Dickinson & Co., Mountain View, CA) at 4~  for 1 h. 
Peptide or anti-DR preincubation were followed  by labeling with 
FITC-avidin D (10 #g/ml; 100 #1; Vector Labs, Burlingame, CA) 
at 4~  for 30 min. Incubation with FITC-avidin D was followed 
by incubation  ofbiotinylated  anti-avidin  D (10 #g/ml; 100/A; Vector 
Labs) and FITC-avidin D again. After each incubation, excess re- 
agents were washed off at 4~  using PBS containing 0.1% BSA. 
Stained cells were analyzed  by flow cytometry on a FACScan  |  ana- 
lyzer (Becton Dickinson & Co.). Dead cells were excluded from 
the analysis  by propidium iodide staining. To measure the relative 
amount of FITC-avidin D bound, the mean fluorescence  of 5,000 
stained cells was determined. Background fluorescence, measured 
in the absence of peptide, was subtracted. 
mAbs.  The following mAbs were used in this study: anti-DR 
(B8.11.2); anti-class  I  (W6/32);  anti--class II  (1C2); anti-DQ 
(SPVL3); anti-DP (B7/21); anti-DR52  (7.3.19.1). All antibodies 
were used in a final concentration comparable with the ascites so- 
lution diluted 1:100 (in the binding assays) and 1:200 (in T cell 
proliferation assays). As a control, nonimmune mouse ascites were 
tested. 
T Cell Proliferation  Assays.  Proliferation  was assayed  by mixing 
104 T cells, irradiated DR-matched allogeneic PBMC (5  x 104/ 
well), or EBV-BLCL (3  x  104/we11) and antigen in 96-well fiat- 
bottomed microtiter plates in triplicate. After 66 h of  culture, 1 #Ci 
[3H]thymidine was added to each well, and 18 h later cells were 
collected on glass fiber strips, and the radioactivity incorporated 
into the DNA was determined  by liquid scintillation  counting. Mean 
and SEMs were computed from the cpm of triplicate tests. 
Competition Experiments.  Inhibition of activation of the HLA- 
DR17-restricted, p3-13-reactive T cell  clone CAAp15 1-1 was studied 
in  T  cell proliferation assays by mixing  104  T  cells, irradiated 
PBMC (5  x  104/we11), derived from rhesus macaques, stimulator 
peptide (10 ng/ml) and competitor peptide (final concentration: 
0.1-, 1.0-, 10-, 100- and 1,000-fold  excess relative to the stimulator 
pe10tide 103-13). Toxicity of competitor peptides, for either T cells 
or APC, was checked by mixing either T cells (104/well) and 10% 
IL-2 (Lymphocult-T;  Biotest, Frankfurt, Germany) or PBMC (5 x 
104/we11) and 0.5% PHA (Wellcome  Diagnostics, Dartford, UK) 
with competitor peptide (final concentration, 10 #g/ml). To ex- 
clude the possibility that the nonresponsiveness  to the competitor 
pe10tides was due to toxicity of those peptides for either the T cells 
or the APC, we tested the influence of these 10eptides on both the 
IL-2-dependent activation of the HLA-DR17-restricted T cells and 
the PHA-induced proliferation of the APC. The presence of the 
competitor pe10tides did not result in reduction of proliferation of 
the T cells nor did it disturb the activation by PHA. 
Nonhuman Primate  Mhc Nomenclature  and Cells.  The chimpanzee 
and rhesus macaque Mhc's have recently been designated MhcPatr 
and MhcMamu, respectively  (23), Official  locus and names of  chim- 
panzee and rhesus macaque  Mhc class II alleles  were given according 
to the rules formulated by the nonhuman primate Mhc nomencla- 
ture committee and were based on similarities  between HLA-DRB 
(human), Patr-DRB (chimpanzee) (20), and Mamu-DRB (rhesus 
macaque) (21) sequences. The Mamu-DR specificities  depicted in 
Fig. 1 were determined by serologic and RFLP techniques. For 
example, the DR1 specificity  was determined by serology, and the 
A, B, C, and D designations that may follow represent subtypes 
defined by RFLP (24). Alloantisera that recognize Patr-DR mole- 
cules are at present not available. The Patr-DR types of various 
chimpanzees that are shown in Fig. 1 have  been determined  by RFLP 
(25). There is no obvious relationship between serologic HLA-DR 
specificities and serologically  or RFLP-determined Patr- or Mamu- 
DR types, meaning that the nonhuman primate DR specificities 
have been named arbitrarily. 
The human homozygous typing EBV-BLCL  used in this study 
are: OOS (HLA-DR1/Dwl), HAR (HLA-DR17, DR52a), and 
AVL (HLA-DR17, DR52a). The following chimpanzee cells have 
been used and corresponding relevant sequence information (if 
present)  and  typings  are  depicted: Yvonne (Patr-DRBl*0204, 
-DRBI*O307/DR4,5),  Gwen  (-DRBI*0305/DR10),  Louise 
(DRB*0201/DR4),  Debbie (-DRBI*0701/DR9,10),  Annette 
(-DRBl*0201,  -DRBl*0309/DR2,8),  Pearl (-DRBl*0203, 
-DRBI*0306/DR4B,7),  Wodka (-DRBl*0201,  -DRBS*0102/ 
DR1,4),  Sherry (-DRBI*I00I/DR3,4),  Dennis  (-DRBI*0204/ 
DR4B,4C), Brigitte (-DRBX*0102, -DRBI *0702, DRB4*0201/ 
DR9,12), Victoria (-DRBl*O308/DR13). EBV-BLCL  of the next 
rhesus macaques, homozygous for Mamu-A, -B, and -DR, were 
derived from  the  Institute  of Applied Radiobiology and  Im- 
munology-TNO  colony:  1WM  (Mamu-DRBt*0303/DR1A), 
JY  (-DRBl*0405/DR1B),  1RK  (not  sequenced/DR2),  3C 
(-DRBl*0309/DR3A),  1KM  (-DRBl*0306/DR3C),  2Y  (not 
980  Primate  MHC-Peptide-TCR  Interactions sequenced/DR4),  1MC  (DRBI*O404/DK5C,5D), 3081 (not 
sequenced/DIL6),  2849 (-DRBwS*OIOI/DRTA),  2B (-DRB1*0310/ 
DR8),  1ZA (-DRBI*O305/DR9). 
Results 
Binding of hsp65 p3-13 and Hemaggtutinin (HA) p307-319 
to EBVBLCL  Derived  from Chimpanzees and Rhesus Ma- 
caques.  Hsp65 p3-13 of Mycobacterium leprae  and M. tubercu- 
losis functions as an important T cell epitope only in HLA- 
DR17-positive individuals (11), since it selectively binds to 
(a pocket in) DR17 molecules (12). It is anticipated that the 
presence of certain polymorphic amino acid residues (motifs) 
in the highly polymorphic DRB1 chain, situated in the MHC 
class II peptide binding site, is required for binding of p3-13 
(13). To measure the binding of p3-13 to different Mamu- 
DR and Patr-DR molecules, 11 different DR homozygous 
rhesus  macaque  and 11 disparate chimpanzee EBV-BLCL, 
selected for distinct DR specificities, were pulsed with bi- 
otinylated hsp65  p3-13. As a control for binding, the bi- 
otinylated analogue of the influenza HA peptide p307-319 
(PKYVKQNTLKLAT) was used. This peptide is recognized 
by a HLA-DRl-restricted T cell clone (26) and is known to 
bind well to most or all HLA-DR molecules other than HLA- 
DR17 (22). 
The results of the binding experiments with the nonhuman 
primate BLCL are shown in Fig. I. For reference purposes 
the data for HLA-DR17-positive  and -DR.l-positive BLCL, 
good binders for p3-13 and HA p307-319, respectively (12), 
are also shown. For the chimpanzee-derived BLCL, binding 
of p3-13 is only found for cells with the Patr-DR13 specificity, 
whereas none of the other cell lines reach significant levels 
of binding (Fig. 1 A). P3-13 binds to 3 of the 11 rhesus ma- 
caque cells tested with the specificities  Mamu-DR1, -DR3C, 
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Figure  1.  Binding of the biotinylated analogues of hsp65 p3-13 (A and B) and HA p307-319 (C and D) to the surface of living EBV-BLCL. Results 
of binding for BLCL from chimpanzees (,4 and C) and rhesus macaques (B and D) given in filled bars, for human BLCL, in striped bars. Values on 
the y-axis represent the mean fluorescence intensity, corrected for background fluorescence. Background fluorescence, determined in the absence of 
BLCL by incubation medium with FITC-avidin D, is indicated by a dash on the x-axis. The MHC specificities are given on the x-axis. Sequencing 
demonstrated that rhesus monkeys with the DR1, DtL3C, and DR9A specificities  are positive for the Marau-DRBl*0303, -DRBI *0306, and -DRBI*0308 
alleles, respectively, whereas the Patr-DR13 specificity is associated with a Patr-DRBI  *0308 allele. More detailed information on the MHC typing of 
various chimpanzees and rhesus macaques is given in Materials and Methods. The results represent the mean of three independent experiments. 
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Figure 2.  Alignment of the deduced amino acid sequences of relevant HLA-, Parr-, and Mamu-DRB  second exon sequences (20, 21, 51). Sequences 
were obtained from references 20 and 21. As a consensus sequence the HLA.DRBI*0101 allele is used. Differences with this consensus are given by 
letter substitutions,  while dashes refer to identical amino acid residues. The regions that are important for p3-13 binding have been boxed, whereas 
the motifs important for binding are printed in bold. 
and -DR9A (Fig.  1 B).  In contrast,  HA p307-319 binds to 
all nonhuman EBV-BLCL tested, although the level of fluores- 
cence  varies (Fig.  1,  C  and D). 
Comparison of  Mhc-DRB1 Sequences  of  Human, Chimpanzee, 
and Rhesus Macaque.  Since  the  polymorphic  amino  acid 
residues of MHC-DRB molecules involved in binding pep- 
tides are likely to be located in the hypervariable regions of 
the DRIll chain (4), the amino acid sequences of the second 
exons of relevant HLA-, Patr-, and Mamu-DRB gene prod- 
ucts were aligned (Fig.  2). One would expect  that the var- 
ious p3-13 binding MHC-DRB chains share specific amino 
acid residues important for binding. As can be seen, all DR3 
chains capable of binding p3-13  (Patr-DRBl*0308, Mamu- 
DRBI*0303,  -DRBI*0305,  and -DRBI*0306) share two 
motifs namely at positions 9-13  (EYSTS)  and 26-31  (YL- 
DRYF), which therefore seem to be important for binding 
(Fig. 2). These important motifs for p3-13 binding have been 
indicated in Fig. 3, depicting the hypothetical antigen-binding 
site of MHC class II molecules. 
A single mutation, 26Y-*F, as seen in Patr-DRB1  *0302, 
-0305, -0306, 0307, and -0309 abrogates binding of p3-13 
completely.  These data extend the observation on the substi- 
tutions of 26Y-*F and 28D~E,  which are the only differ- 
ences in the second exon ofHLA-DRBI*0301 (HLA-DR17) 
vs. HLA-DRBl*0302 (HLA-DR18) in humans and abrogates 
binding of p3-13  as well (Fig.  2, and reference 12). 
Various differences between the primate MHC-DRB mol- 
ecules  that  are able to bind p3-13, located  at positions 32 
(H--,.Y),  37 (N--~Y), 47 (F--~Y),  57 (D--~V,H), 60 (Y"~S), 
61  (W--~Y),  67  (L--~Y,I), 68  (L--~V),  70  (Q---~D), 71 
(K--~E,Q), 73 (G-*h), 74 (K--~A,S), 77 (N---,T),  78 (Y--~F), 
84  (G-*R),  and  86  (V--~G,A,C,F),  do  not  significantly 
influence peptide binding. Most of these residues do not map 
within the two motifs important for binding of this partic- 
ular peptide  (4),  as  can be seen in Fig.  3. 
/%, 
:_~)  "" ?  ,j~  .,. 
Figure 3.  Schematic representation of the hypothetical model of the 
antigen-binding site of MHC class II molecules, showing the important 
conserved (black) and variant (white) residues involved in p3-13 binding. 
Circles represent amino acid residues that lie in the fl-pleated sheet; squares 
represent amino acid residues that are part of the a-helical structure  of 
the molecule. 
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Presented  by  MHC-DR17-1ike Nonhuman Primate-derived 
BLCL.  The results above indicate that the two motifs for 
p3-13 binding  have been conserved in evolution within  at 
least part of the Mhc-DRBI *03 lineage members. Mhc-peptide 
complexes are recognized by T  cells only in the context of 
sdf-MHC, a phenomenon known as MHC restriction (27). 
In this light it was investigated whether, apart from the crit- 
ical peptide-binding residues,  polymorphic residues for T cell 
recognition had also been conserved in evolution. In that case, 
one would expect that T  ceils that are selected to see p3-13 
in  the context  of HLA-DR17 may recognize  this  peptide 
presented by some nonhuman equivalents that bind the pep- 
tide.  To test this hypothesis the capacity of the BLCLs of 
1WM (Mamu-DRBI*0303), 1KM (Mamu-DRB1  *0306), 1ZA 
(Mamu-DRBl *0305), and Victoria (Patr-DRB1  *0308), which 
all  bind  p3-13,  to  present  the  peptide  to  a  HLA-DK17- 
restricted, p3-13-reactive T call clone, CAAp15 1-1, was ana- 
lyzed in a T  cell proliferation  assay (Fig.  4).  As a positive 
control human PBMC (DK2,3) were used as APC. All APC 
were tested for presentation of hsp65 p418-427 to the hsp65- 
reactive, DK2-restricted T cell done K2F10 (28). As a nega- 
tive control rhesus macaque BLCL that did not bind p3-13 
(Fig.  1), such as 1MC (Mamu-DRBl*0404) and 2849 (Mamu- 
DRBw8*0101), were used as APC as well. All BLCL derived 
from rhesus macaques that  are able to bind p3-13 are also 
able to present  the peptide to the p3-13-reactive human  T 
cell done (Fig.  4). Thus, the peptide not just binds to these 
cells but can also be presented by these nonhuman  primate 
HLA-DR17-1ike alleles  and give rise to T  cell recognition 
and proliferation. BLCL of Victoria (Patr-DRB1*0308),  how- 
ever,  are  not  able to present  p3-13 to human  T  cells  (Fig. 
4). This indicates that although the p3-13 binding residues 
are conserved in this chimpanzee-derived allde, the TCR con- 
tact residues or, alternatively, the conformation of the mole- 
cules have not remained the same. As expected, the nonbinding 
BLCL did not activate the T cells. None of the APC tested, 
except for the heterozygous human PBMC (DR2,3),  were 
able to present  the DR2-specific peptide,  hsp65 p418-427, 
to the HLA-DK2-restricted  human T  cell clone K2F10. 
Inhibition of  p3-13-mediated  T Cell  Activation of  a HLA-DRI 7- 
restricted T Cell Line by mAbs.  To confirm the specificity of 
the binding of p3-13 to the rhesus macaque DR molecules, 
we coincubated  p3-13  with  either  or-DR,  c~-DP,  c~-DQ, 
or-DR52, a-class I, or or-class  II mAbs in T  cell prolifera- 
tion assays using either HLA-DR17-positive or Mamu-DK- 
positive EBV-BLCL as APC (Fig.  5). Here, it is evident that 
binding of p3-13 is inhibited only by or-DR, or-DR52, and 
or-class II backbone mAbs. Thus, as expected, the presenta- 
tion ofp3-13 is HLA-DRBI*03 restricted. The fact that the 
binding is also blocked by or-DR52 seems to be unexpected 
since 7.3.19.1  reacts with residue 73 (Gly) of DRB1, which 
is present on some Mhc-DRBI*03 and -DRB3 molecules (29). 
Examination of the Mamu-DRB1*0305  allele, however, shows 
the absence of the epitope for 7.3.19.1 binding (Fig, 2). Thus, 
in this particular case, T cell proliferation is probably inhibited 
by steric hindrance because mAb 7.3.19.1 binds to the MHC 
class II molecules of the human T  cell,  which does express 
the epitope in question. 
Competition Experiments.  Peptides with single amino acid 
substitutions,  which are able to bind to MHC molecules, 
may not activate T cells (30-32).  Such competitor peptides 
of hsp65, p4-13, have been demonstrated to inhibit the HLA- 
DR17-restricted T cell response of p3-13-reactive  T cell clones 
(33). These peptides were now tested for their ability to in- 
hibit the response of T  cell clone CAAp15  1-1 to p3-13 in 
the context of rhesus macaque-derived PBMC. The results 
of the competition experiment  are shown in Fig. 6. P4-13 
substituted at position 6 (A--~Q) was able to inhibit the re- 
sponse induced by p3-13. A control peptide, p4-13 (8D--P), 
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Figure 4.  Effect  on T call proliferation  of the hsp65 p3-13-reactive,  DK17-restricted  clone, CAAp15 1-1 (A), and the hsp65 p418-427 (LQAAPALDKL)- 
reactive, DR2-restr/cted  done, K2F10 (28) (B). Peptides  are presented  by four different  APC. Proliferation assays  were  performed  as described  in Materials 
and Methods. The APC used, given on the x-axis, are human heterozygous  PBMC named Leen (HLA-DK2,3) and rhesus macaque-derived  EBV-BLCL 
LKM (Mamu-DK3C), 1ZA (-DR9), 1WM (-DK1), 1MC (-DKS) and 2849 (-DK7). 
983  Geluk  et al. Figure 5.  Inhibition  of hsp65 p3-13-stimulated activation of the PPD- 
reactive T cell line v.Es-Menken (HLA-DR2,3)  by r  cr  ot-DP, 
~-DK52, c~-class  I, and c~-class  II. The mAbs are indicated on the x-axis. 
EBV-BLCL used as APC are AVL (HLA-DK17) and 1ZA (Mamu-DR9). 
Proliferation is expressed on the y-axis (cpm). 
which does not bind to HLA-DR17, was not able to inhibit 
the T  cell response  at  all. 
Discussion 
Humans, chimpanzees, and rhesus macaques are primate 
species that share a progenitor that lived '~30 million yr ago 
(34). The divergence between humans and chimpanzees took 
place •5-7  million yr ago (35). Consequently, these closely 
related species may share highly similar immune systems. Se- 
quencing studies have demonstrated that many MHC poly- 
morphisms predate speciation,  supporting the trans-species 
hypothesis (18), and indicating that some of the polymor- 
cpm 
2000 
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0  0.1 
i  J  J 
1.0  10  100  1000 
competitor  peptide (ng/ml) 
Figure 6.  Inhibition  of hsp65 p3-13 (10 ng/ml) -stimulated activation 
of DR17-restricted T cell clone CAAp15 1-1 by a single amino acid sub- 
stituted analogue of 1M-13. Inhibition peptide concentration is indicated 
on the x-axis. Proliferation is expressed on the y-axis (cpm). Stimulation 
index for competitor  peptides without p4-13 were gl. Experience with 
nonhuman primate cells taught that proliferative responses using PBMC 
as APC are generally lower than when BLCL are used. 
phisms are relatively old and represent stable structures. The 
finding that MHC class II polymorphism is maintained by 
strong selective forces (36-39)  implies that polymorphism 
must have some important function. The biologic significance 
of polymorphism observed within Mhc class II lineages was 
investigated by Mhc-peptide binding and T cell proliferation 
assays. 
Here it is demonstrated that humans, chimpanzees,  and 
rhesus macaques have particular Mhc-DRBl*03 lineage mem- 
bers in common. Only Mhc-DRBl*03 molecules that con- 
tain residues 9-13 (EYSTS) and 26-31 (YLDRYF) are able 
to bind p3-13. This indicates that at least two motifs are neces- 
sary for effective p3-13 binding (Fig. 2). As can be seen, the 
absence of one of these motifs at 9-13  (EYSTS), as found 
in HLA-DRB3*0101, diminished  p3-13 binding significantly. 
Apart from other residues, a critical residue for p3-13 binding 
is 26 (Y), as the substitutions at this position (Y--F) abrogates 
p3-13 binding (Fig. 2). The presence of residue 26 (Y), how- 
ever, is, on its own, not enough for p3-13 binding as is demon- 
strated by the lack of p3-13 binding for HLA-DRBI*0901, 
Patr-DRBl *0102, Mamu-DRBI *0402, and -DRB3 *0401. 
The positively charged residues 71 (K) and 74 (R) are not 
present in other HLA alleles besides HLA-DRBI*03,  and are 
supposed to be located in the peptide-binding site (4). There- 
fore, it was proposed that these residues could contribute to 
p3-13 binding by interacting with the negative charge on the 
peptide (12). However, by using nonhuman primate BLCL, 
we now demonstrate that p3-13 binding can occur also to 
Mhc alleles Patr-DRBl*0308 and Mamu-DRBl*0303, which 
lack positively charged residues such as 71 (K) and 74 (R,). 
MHC molecules bearing the combination of 9-13 (EYSTS) 
and 26-31 (YLDRYF) motifs described above are present in 
human, chimpanzee, and rhesus macaque populations. This 
indicates  that they may have been selected as polymorphic 
peptide contact residues (motifs) in the population in order 
to preserve binding of certain epitopes from important patho- 
gens. Here one such combination is described. However, we 
envisage that other preferential MHC-peptide combinations 
may have been conserved within distinct primate species as 
well. 
The reason for this interspecies  conservation of class II motifs 
may have resulted from the fact that these related species can 
share the same pathogenic threats like mycobacterial  infec- 
tions (40). Thus, some Mhc-DRB lineages, present in different 
primates, might have been maintained due to a selective ad- 
vantage with regard to diseases, as described for HLA-B53 
and severe malaria in West Africa (41). This may also be the 
case for mycobacterial diseases, notably tuberculosis cases that 
have been described in nonhuman primates (42). In addition, 
it has been reported that both chimpanzees (43) and rhesus 
macaques (44) can develop leprosy in experimental models, 
but even cases of naturally acquired leprosy in chimpanzees 
have been documented (45). These examples emphasize that 
distinct but closely related  species may suffer from shared 
pathogenic threats and diseases. Mycobacteria  are important 
pathogens, and immunity against these pathogens is strictly 
T  cell dependent both in healthy and in mycobacterial  dis- 
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hsp65 that is seen as a T cell epitope in HLA-DR17-positive 
individuals (11). The conservation of a peptide-binding pocket 
for this immunodominant hsp65 peptide to primates of the 
Mhc-DRBI *03 lineage may reflect the importance of the T 
cell recognition of the peptide in the context of the same 
MHC molecules and the consequent survival of these species. 
Nonhuman primate MHC molecules from rhesus macaques 
were not only able to bind p3-13 but also to present this pep- 
tide to HLA-DR17-restricted, p3-13-reactive human T  cell 
clones (Fig.  4). This indicates that p3-13 probably binds in 
the same conformation to nonhuman primate-derived BI.CL 
and that besides the Mhc-peptide binding residues, the Mhc- 
TCR contact residues have also been conserved. However, 
the chimpanzee allele  that  showed positive binding,  Patr- 
DRBI*0308, could not present p3-13 to human T cells. This 
indicates that either p3-13 binding residues have been con- 
served in this allele and that the TCR contact residues have 
not, or that this peptide binds in a different conformation 
to the MHC molecule, which is not recognized by the TCR. 
The B-pleated sheet and ol helix sections of the second do- 
main of MHC class II molecules appear to have different evolu- 
tionary histories (17). Especially, the B-pleated sheet-associated 
polymorphisms have been conserved between species whereas 
the ot helix accumulated considerably more variation (46). 
The  present  data  suggest  that  the  B-pleated  sheet  sec- 
tion-encoded polymorphisms have been maintained in evo- 
lution because they encode motifs that are essential for the 
binding of some peptides needed to initiate an immune re- 
sponse. The ~  helix section of MHC class II molecules is 
probably recognized by the TCR.  Since one individual en- 
codes a high amount of different T cell receptors, the chance 
that nonresponsiveness  is induced by amino acid replacements 
in the ot helix sections is relatively low. For that reason the 
ot helix is probably allowed to accumulate more variation than 
the ~-pleated sheet. 
The conservation of MHC class II molecules for *30 mil- 
lion yr stands in contrast to the relatively fast evolution of 
some MHC class I molecules, as HLA-B antigens (47,  48). 
This is may be due to the difference in origin of the antigens 
presented by either MHC class I or II molecules being en- 
dogenous and exogenous peptides, respectively. Since endog- 
enous viral peptides change rapidly, the MHC class I mole- 
cules that present those peptides may have to adapt fast to 
avoid that, or such pathogens may escape CTL recognition. 
However,  peptides  derived  from  exogenous  antigens  are 
selected by MHC class II molecules after binding one of the 
polymorphic immunoglobulins on B cells and subsequent pro- 
cessing.  Therefore, peptides with a more conserved nature 
can be selected to initiate antibody response, as is exemplified 
by the conservation of a peptide binding site for >30 million 
yr for the Mycobacterium-derived hsp65 p3-13. 
Furthermore, the p3-13 reactive T cell response of the HLA- 
DR17-restricted T cell clone CAAp15 1-1, which possesses 
the TCR VB1 segment, could be inhibited with specific, single 
amino acid substitution analogues of hsp65 p4-13 (33) using 
rhesus monkey--derived PBMC that were able to bind to p3-13 
as APC. In this context it is relevant to note that not only 
the MHC may be highly similar in primate species but that 
equal observations may be done for other systems that are 
important for immune recognition. Recently, it was docu- 
mented that rhesus macaques possess  TCR V/31 segments 
that  show 95.6  and 96%  nucleotide similarity with their 
human equivalent (49). The observations described above dem- 
onstrate that human and nonhuman primate species share 
highly similar immune systems.  As the HLA-DR3 allele is 
associated with several autoimmune and allergic diseases, such 
as SLE,  celiac disease,  insulin-dependent diabetes mellitus, 
and Graves' disease (50),  the finding of comparable peptide- 
presenting capacity and specificity for certain nonhuman pri- 
mate--derived APC could, therefore, open possibilities to study 
means of preventing HLA-DR3-associated diseases at a preclin- 
ical stage in experimental models of autoimmune disease in 
nonhuman primates. 
We thank Drs. F. Koning and J. E. R. Thole for critically reading the manuscript. 
This study was supported by the Science and Technology for Development Programme of the European 
Community (TD2-191-NL), the Netherlands Organization for Scientific Research, the United Nations 
Development Program/World Bank/World Health Organization  Special Programme for Research and 
Training in Tropical Diseases. The J. A. Cohen Institute for Radiopathology and Radiation Protection, 
and the Dutch Leprosy Relief Association. 
Address correspondence to A. Geluk, Department of Immunohematology and Bloodbank, University 
Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands. 
Received for publication 13 October 1992 and in revised form 3 December 1992. 
R~ferences 
1.  Unanue, E.R. 1984. Antigen-presenting function of the mac- 
rophage. Annu. ~  Iraraunol. 124:533. 
2.  Schwartz, R.H.  1985. T-lymphocyte recognition of antigen 
985  Geluk  et al. 
in association with gene products of the major histocompati- 
bility complex. Annu. Rev. Imraunol. 3:237. 
3.  Buus, S., A. Sette, and H.M. Grey. 1987. The interaction be- tween protein-derived  immunogenic peptides and Ia. Immunol. 
Rev. 98:115. 
4.  Brown, J.H., T. Jardetzky, M.A.  Saper, B. Samraoui, P.J. 
Bj6rkman, and D.C. Wiley. 1988. A hypothetical model of 
the foreign antigen binding site of the class II histocompati- 
bility molecules. Nature (Lond.). 332:845. 
5.  Bj6rkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennet, J.L. 
Strominger, and D.C. Wiley. 1987. Structure of the human 
class I histocompatibility antigen, HLA-A2. Nature  (Lond.). 
329:506. 
6.  Young, D.B., R. Lathigra, R. Hendrix, D. Sweetser, and R.A. 
Young. 1988. Stress proteins are immune targets in leprosy 
and tuberculosis. Proc. Natl. Acad. Sci. USA.  85:4267. 
7.  Ottenhoff, T.H.M., B. Kale Ab, J.D.A. van Embden, J.E.R. 
Thole, and R. Kiesling. 1988. The recombinant 65-kD heat 
shock protein  of  Mycobacterium  bovis bacillus Calmette- 
Guerin/M. tuberculosis is a target molecule  for CD4 + cytotoxic 
T  lymphocytes that lyse human  monocytes. J.  Exp.  Med. 
168:1947. 
8.  Ottenhoff,  T.H.M., J.B.A.G. Haanen, A. Geluk, T. Mutis, 
B. Kale Ab, J.E.R. Thole, W.C.A. van Schooten, P.J. van der 
Elsen, and R.R.P. de "Cries. 1991. Regulation of Mycobacterial 
heat shock protein-reactive  T cells  by HLA class II molecules: 
lessons from leprosy. Irnmunol. Rev. 121:171. 
9.  Lamb, J.R., V. Bal, P. Mendez-Sempario, A. Mehlert, A. So, 
J. Rothbard,  S. Jindal, R.A. Young, and D.B. Young. 1989. 
Stress proteins may provide a link between the immune re- 
sponse to infection and autoimmunity. Int.  Immunol.  1:191. 
10.  Thole, J.E.R., W.J. Keulen, A.H.J.  Kolk, D.G. Groothuis, 
L.G. Berwald, R.H. Tiesjema, andJ.D.A. Van Embden. 1987. 
Characterization, sequence  determination and immunogenicity 
of a 64-kilodalton  protein ofMycobacterium bovis  BCG expressed 
in Escherichia coli K12. Infect. Immun.  55:1466. 
11.  Van Schooten, W.C.A., D.G. Elferink, J. Van Embden, D.C. 
Anderson, and R.R.P. De Vries. 1989. DR3-restricted T cells 
from different HLA-DR3-positive individuals recognize the 
same peptide (amino acids 2-12) of the mycobacterial  65-kDa 
heat-shock protein. Eur. J. Immunol.  19:2075. 
12.  Geluk, A., W. Bloemhoff, R.R.P. De Vries, and T.H.M. Ot- 
tenhoff. 1992. Binding of a major T cell epitope of mycobac- 
teria to a specific pocket within HLA-DRw17(DR3) mole- 
cules. Eur. J. Immunol.  22:107. 
13.  Lawlor, D.A., F.E. Ward, P.D. Ennis, A.P. Jackson, and P. 
Parham. 1988. HLA-A  and B polymorphisms  predate the diver- 
gence of humans and chimpanzees. Nature (Lond.). 353:268. 
14.  Mayer,  W.E., M. Jonker, D. Klein, P. Ivanyi, G. Seventer, and 
J. Klein. 1988. Nucleotide sequences of  chimpanzee  MHC class 
I alleles: evidence  for transspecies mode of evolution. EMBO 
(Eur. Mol. Biol. Organ.).].  7:2765. 
15.  Watkins, D.I., Z.W. Chen, A.L. Hughes, M.G. Evans, T.F. 
Tedder, and N.L. Letvin. 1990. Evolution of the MHC class 
I genes of a New World primate from ancestral homologues 
of human non-classical genes. Nature (Lond.). 346:60. 
16.  Fan, W., M. Kasahara,  J. Gutknecht, D. Klein, W.E. Mayer, 
M. Jonker, and J. Klein. 1989. Shared  class II MHC polymor- 
phism between  humans  and chimpanzees. Hum.  Immunol. 
26:107. 
17.  Gyllensten, U.B., M. Sundvall, I. Ezcurra, and H.A. Erlich. 
1991. Genetic diversity at class II DRB loci of the primate 
MHC. J.  Immunol.  146:4368. 
18.  Klein, J. 1987. Origin of major histocompatibility complex 
polymorphisms: the transspecies hypothesis. Hum. Immunol. 
19:155. 
19.  Otting, N., M. Kenter, E van Weeren, M. Jonker, and R.E. 
Bontrop. 1992. Mhc-DQB repertoire  variation  in hominoid and 
Old World primate species.  J. Immunol.  149:461. 
20.  Kenter, M., N. Otting, J. Anholts, M. Jonker, R. Schipper, 
and R.E. Bontrop. 1992. Mhc-DRB diversity  of the chimpanzee 
(Pan troglodytes). Immunogenetics. 37:1. 
21.  Slierendregt, B.L.,  J.T. van Noort, R.M. Bakas, N. Otting, 
M. Jonker, and R.E. Bontrop. 1992. Evolutionary stability of 
trans-species major histocompatibility complex class II DRB 
lineages in man and rhesus monkey. Hum. Immunol.  35:29. 
22.  Busch,  R., G. Strang, K. Howland, andJ.B. Rothbard. 1990. 
Degenerate  binding of  immunogenic  peptides to HI,  A-DR pro- 
teins on B cell surfaces. Int.  Immunol.  2:443. 
23.  Klein, J., R.E. Bontrop, R.L. Dawkins, H.A. Erlich, U.B. 
Gyllesten, E.R. Heise, P.P. Jones, P. Parham, E.K. Wakeland, 
and D.I. Watkins. 1990. Nomenclature for the major histocom- 
patibility complex of different species: a proposal. Immuno. 
genetics. 31:217. 
24.  Slierendregt, B.L., N. Otting, M. Jonker, and R.E. Bontrop. 
1991. RFLP analysis of the rhesus monkey Mhc class II DR 
subregion. Hum. Immunol.  30:11. 
25.  Bontrop, R.E., L.A.M. Broos, K. Pham, R.M. Bakas, N. Ot- 
ting, and M. Jonker. 1990. The chimpanzee major histocom- 
patibility complex class II DR subregion contains an unex- 
pectedly high number of beta-chain genes. Immunogenetics. 
32:272. 
26.  Rothbard, J.B., R. Busch, K. Howland, V. Bal, C. Fenton, 
W.R. Taylor, and J.R. Lamb. 1989. Structural analysis of a 
peptide-HLA class II complex: identification of critical inter- 
actions for its formation and recognition by T cell receptor. 
Int.  Immunol.  1:479. 
27.  Zinkernagel, R.M., and PC. Doherty.  1974. Restriction of 
in vitro T cell mediated cytotoxicity in lymphocytic chorio- 
meningitis within a syngeneic or allogeneic system. Nature 
(Lond.). 284:701. 
28.  Anderson, D.C., W.C.A. Van Schooten, A.A.M.Janson, M.E. 
Barry, and R.R.P. De Vries. 1990. Molecular mapping of in- 
teractions between a Mycobacterium leprae-specific T cell epi- 
tope, the restricting HLA-DR2 molecule, and two specific  T 
cell receptors. J. Immunol.  144:2459. 
29.  Bontrop, R.E., D.G. Elferink, N.  Otting, M. Jonker, and 
R.R.P. de Vries. 1990. Major histocompatibility  complex  class 
II-restricted antigen presentation across a species barrier: con- 
servation of restriction determinants in evolution.J. Exp. Med. 
172:53. 
30.  Werdelin, O. 1982. Chemically related antigens compete for 
presentation by accessory  cells to T cells.J. Immunol. 129:1883. 
31.  Rock, K.L., and B. Benacerraf. 1983. Inhibition of antigen- 
specific T lymphocyte  activation  by structurally related Ir gene- 
controlled polymers. Evidence of specific competition for ac- 
cessory cell antigen presentation. J. Extz Med.  157:1618. 
32.  Babbitt, B.P., G. Matsueda, E. Haber, E.R. Unanue, and P.M. 
Allen. 1986. Antigenic competition at the level of peptide-IA 
binding. Proc. Natl. Acad. Sci. USA.  83:4509. 
33.  Geluk,  A.,  K.E.  van Meijgaarden, A.A.M. Janson,  R.H. 
Meloen, J. Drijfhout, R.R.P. de Vries, and T.H.M. Ottenhoff. 
1992. Functional analysis  of DR17(DR3)-restricted mycobac- 
terium T cell epitopes reveals  DR17 binding motif  and enables 
the design of allele specific competitor peptides. J. Immunol. 
149:2864. 
34.  Miyamoto, M.M., B.F. Koop,  J.L. Slightom, M. Goodman, 
and M.R. Tennant. 1988. Molecular systematics  of higher pri- 
mates: genealogical  relations  and classifications.  Proa Natl. Acad. 
986  Primate  MHC-Peptide-TCtL  Interactions Sci.  USA.  85:7627. 
35.  Andrews, P. 1986. Fossil evidence on human origins and dis- 
persal.  Cold Spring Harbor Syml~  Quant.  Biol. 51:419. 
36.  Benoist, C.O., D.J. Mathis, M.R. Kanter, V.E. Williams, and 
H.O. Mc. Devitt. 1983. Regions of allelic hypervariability in 
the murine Ac~ immune response gene. Cell. 34:169. 
37.  Hughes, A.L., and M. Nei. 1989. Nucleotide substitution at 
major histocompatibility complex class II loci: evidence for over- 
dominant  selection.  Proa Natl. Acad. Sci. USA.  86:958. 
38.  Serjeantson, S.W. 1989. The reasons for MHC polymorphism 
in man.  Transplant. Proc. 21:598. 
39.  Erlich, H.A., and U.B. Gyllensten. 1991. The evolution of al- 
lelic diversity at the primate major histocompatibility com- 
plex class II loci.  Hum. Immunol.  30:110. 
40.  Klein, J. 1991. OfHLA, tryps, and selection: an essay on coevo- 
lution of MHC and parasites.  Hum. ImmunoL  30:247. 
41.  Hill, A.V.S., C.E.M. Allsopp, D. Kwiatkowski, N.H. Anstey, 
P.  Twumasi,  P.A.  Rowe,  S.  Bennett,  D.  Brewster,  A.J. 
McMichael,  and  B.M.  Greenwood.  1991. Common  West 
African antigens are associated  with protection from severe 
malaria.  Nature (Lond.). 352:595. 
42.  Mulder, J.B. 1976. Tuberculosis in non-human primates.  Vet. 
Med.  Small Anita.  Clin.  71:1286. 
43.  Gunders, A.E. 1958. Progressive experimental infection with 
Mycobacterium leprae in a chimpanzee. A preliminary report. 
J.  Tro  F  Med.  Hyg.  61:228. 
44.  Wolf, R.H., B.J. Gormus, L.N. Martin,  G.B. Baskin,  G.P. 
Walsh, W.M. Meyers, and C.H. Binford. 1985. Experimental 
leprosy in three species of monkeys. Science (Wash. DC). 227:529. 
45.  Leiniger, J.R., K.J. Donham, and M.J. Rubino. 1978. Leprosy 
in chimpanzee. Morphology of the skin lesions and character- 
ization of the organism.  Vet. Pathol. 15:339. 
46.  Sigurdardottir, S., C. Borsch, K. Gustafsson, and L. Andersson. 
1992. Exon encoding the antigen-binding site of MHC class 
II/3-chains is divided into two subregions with different evolu- 
tionary histories, j.  Immunol.  148:968. 
47.  Belich, M.P., J.A. Madrigal, W.H. Hildebrand, J. Zemmour, 
R.C. Williams, R. Luz, M.L. Petzi-Erler, and P. Parham. 1992. 
Unusual HLA-B alleles in two tribes of Brazilian Indians. Na- 
ture (Lond.). 357:326. 
48.  D.L. Watkins, S.N. McAdam, X. Liu, C.R. Strang, E.L. Mil- 
ford, C.G. Levine, T.L. Garber, A.L. Dogon, C.I. Lord, S.H. 
Ghim, G.M. Troup, A.L. Hughes, and N.L. Letvin. 1992. New 
recombinant  HLA-B alleles  in  a  tribe  of South  American 
Amerindians indicate rapid evolution of class I loci.  Nature 
(Lond.). 357:329. 
49.  Levison, G., A.L. Hughes, and N.L. Letvin. 1992. Sequence 
and diversity of rhesus monkey T cell receptor/3 chain genes. 
Immunogenetics. 35:75. 
50.  Tiwari, J.L., and P.I. Terasaki.  1985. HLA and Disease As- 
sociations. Springer-Verlag New York Inc., New York, 195 pp. 
51.  Marsh, S.G.E., and J.G. Bodmer. 1991. HLA Class II nucleo- 
tide sequences. Hum. Immunol.  31:207. 
987  Geluk  et al. 